Opus Genetics (R3X1) Price & Analysis

3 Followers

R3X1 Stock Chart & Stats

€3.14

-€0.10(-3.07%)

At close: Jul 31 4:00 PM EDT

€3.14

-€0.10(-3.07%)

Day’s Range― - ―

52-Week Range€1.46 - €5.40

Previous CloseN/A

Volume0.00

Average Volume (3M)298.00

Market Cap

€297.03M

Enterprise Value€405.18M

Total Cash (Recent Filing)€88.81M

Total Debt (Recent Filing)€34.93M

Price to Earnings (P/E)―

Beta0.43

Next Earnings

Nov 17, 2026

EPS Estimate

-0.13

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.27

Shares Outstanding83,195,820

10 Day Avg. Volume309

30 Day Avg. Volume298

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)81.49

Price to Sales (P/S)88.10

P/FCF Ratio-35.48

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€12.26

Price Target Upside290.35% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

EPS Forecast (FY)-0.92

Revenue Forecast (FY)€10.87M

Bulls Say, Bears Say

Bulls Say

Commercial And Regulatory ValidationFDA approval provides Opus with regulatory validation and a milestone payment opportunity from an existing global licensing agreement. Viatris’ exclusive U.S. commercialization rights also give the company a potential route to product economics without requiring Opus to build the entire commercial infrastructure itself.

OPGx-LCA5 Clinical AdvancementSustained improvements in visual acuity and light sensitivity across adult and pediatric participants support the therapeutic rationale for OPGx-LCA5. Advancement into a fully enrolled Phase 3 trial creates a clearer development path and a meaningful opportunity to establish a durable lead in a severe inherited retinal disease.

OPGx-BEST1 Regulatory PathwayFDA alignment on pivotal endpoints and Phase 3 requirements reduces uncertainty around the development framework for OPGx-BEST1. Combined with reported visual and structural improvements, this gives the program a more defined path toward pivotal testing and supports the company’s broader gene therapy pipeline strategy.

Bears Say

Severe Ongoing LossesExtremely negative operating and net margins show that current revenue is far from covering the company’s cost base. The decline in TTM revenue adds pressure to an already unstable earnings profile, leaving Opus dependent on successful clinical and commercial execution before profitability can become sustainable.

Persistent Cash BurnPersistent operating and free-cash-flow deficits indicate that Opus is consuming substantial cash to sustain research and development. Continued negative cash generation increases reliance on external funding and can constrain the pace of investment or reduce financial flexibility during clinical development.

Negative Equity And Rising DebtThe shift from positive equity and no debt to negative equity with meaningful debt materially weakens the balance sheet. This reduces financial flexibility while losses continue, may make future financing more difficult, and increases the importance of securing funding on acceptable terms.

Opus Genetics News

Opus Genetics announces FDA clearance of OPGx-RDH12 IND application

Opus Genetics (IRD) announced that the FDA has cleared its investigational new drug, or IND, application for OPGx-RDH12,...

2d ago

IRD

Opus Genetics reports FDA approval of phentolamine ophthalmic solution 0.75%

Opus Genetics (IRD) announced that the U.S. Food and Drug Administration has approved the company’s supplemental New Drug...

7d ago

IRD

VTRS

Opus Genetics presents clinical findings from its OPGx-BEST1, OPGx-LCA5 programs

Opus Genetics (IRD) presented clinical findings from its OPGx-BEST1 and OPGx-LCA5 gene therapy programs at Retina in Rio...

7d ago

IRD

Opus Genetics management to meet with Oppenheimer

Meeting to be held in New York on October 19 hosted by Oppenheimer. Published first on TheFly –...

10d ago

IRD

Opus Genetics price target raised to $17 from $10 at Jones

Jones raised the firm’s price target on Opus Genetics (IRD) to $17 from $10 and keeps a Buy...

17d ago

IRD

Opus Genetics Announces Transition of Chief Scientific Officer

Opus Genetics ( ($IRD) ) has issued an announcement. Opus Genetics, Inc. reported that Chief Scientific and Development...

1d ago

IRD

Opus Genetics: Advancing BEST1 Program and Targeting Strategy Supports Buy Rating and Unchanged $17 Price Target

Opus Genetics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Debanjana Chatterjee from...

4d ago

IRD

Opus Genetics Advances Gene Therapy Programs With New Data

Opus Genetics ( ($IRD) ) has issued an announcement. On October 14, 2026, Opus Genetics presented new clinical...

7d ago

IRD

Opus Genetics Updates OPGx-BEST1 Trial Data and Outlook

Opus Genetics ( ($IRD) ) has provided an update. On September 11, 2026, Opus Genetics issued a revised...

1M ago

IRD

Thomas Shrader Reiterates Buy on IRD, Maintains $12 Price Target Amid Encouraging Clinical and Regulatory Progress

In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Opus Genetics, with a...

1M ago

IRD

Opus Genetics price target raised to $14 from $11 at Leerink

Leerink raised the firm’s price target on Opus Genetics (IRD) to $14 from $11 and keeps an Outperform...

1M ago

IRD

Opus Genetics price target raised to $20 from $10 at Oppenheimer

Oppenheimer raised the firm’s price target on Opus Genetics (IRD) to $20 from $10 and keeps an Outperform...

1M ago

IRD

Opus Genetics price target raised to $16 from $13 at Chardan

Chardan analyst Andreas Argyrides raised the firm’s price target on Opus Genetics (IRD) to $16 from $13 and...

1M ago

IRD

Yun Zhong Reiterates Buy on Opus Genetics, Lifts Price Target to $13 on Higher Probability of Success for OPGx-BEST1 Program

Wedbush analyst Yun Zhong maintained a Buy rating on Opus Genetics today and set a price target of...

1M ago

IRD

R3X1 FAQ

What was Opus Genetics’s price range in the past 12 months?

Opus Genetics lowest stock price was €1.46 and its highest was €5.40 in the past 12 months.

What is Opus Genetics’s market cap?

Opus Genetics’s market cap is €297.03M.

When is Opus Genetics’s upcoming earnings report date?

Opus Genetics’s upcoming earnings report date is Nov 17, 2026 which is in 25 days.

How were Opus Genetics’s earnings last quarter?

Opus Genetics released its earnings results on Aug 06, 2026. The company reported -€0.125 earnings per share for the quarter, beating the consensus estimate of -€0.14 by €0.015.

Is Opus Genetics overvalued?

According to Wall Street analysts Opus Genetics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Opus Genetics pay dividends?

Opus Genetics does not currently pay dividends.

What is Opus Genetics’s EPS estimate?

Opus Genetics’s EPS estimate is -0.13.

How many shares outstanding does Opus Genetics have?

Opus Genetics has 83,195,820 shares outstanding.

What happened to Opus Genetics’s price movement after its last earnings report?

Opus Genetics reported an EPS of -€0.125 in its last earnings report, beating expectations of -€0.14. Following the earnings report the stock price went down -2.516%.

Which hedge fund is a major shareholder of Opus Genetics?

Currently, no hedge funds are holding shares in DE:R3X1

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Opus Genetics Stock Smart Score

Outperform

Fundamentals

Return on Equity

1147.63%

Trailing 12-Months

Asset Growth

140.44%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Opus Genetics

Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.

Opus Genetics (R3X1) Earnings & Revenues

Historic Earnings Reports

R3X1 Stock 12 Month Forecast

Average Price Target

€12.26

▲(290.35% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","9":"€9","18":"€18","4.5":"€4.5","13.5":"€13.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17.8283946,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€17.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.2570212875,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€12.26</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.13135784,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€7.13</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.5,9,13.5,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.98,5.045261123076923,6.110522246153845,7.175783369230769,8.241044492307692,9.306305615384614,10.371566738461537,11.436827861538461,12.502088984615384,13.567350107692306,14.632611230769228,15.697872353846153,16.763133476923073,{"y":17.8283946,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.98,4.616693945192308,5.253387890384616,5.8900818355769236,6.526775780769231,7.163469725961539,7.800163671153847,8.436857616346154,9.073551561538462,9.71024550673077,10.346939451923078,10.983633397115385,11.620327342307693,{"y":12.2570212875,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.98,4.222412141538461,4.464824283076923,4.707236424615385,4.949648566153846,5.192060707692308,5.434472849230769,5.6768849907692305,5.919297132307692,6.161709273846154,6.4041214153846155,6.646533556923076,6.888945698461539,{"y":7.13135784,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.52,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.958,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.706,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.656,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.95,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.695,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.055,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.26,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.48,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.62,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.16,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.24,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.98,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >